Cover Image
市場調查報告書

濾泡型淋巴瘤:開發平台分析

Follicular Lymphoma - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 229752
出版日期 內容資訊 英文 542 Pages
訂單完成後即時交付
價格
Back to Top
濾泡型淋巴瘤:開發平台分析 Follicular Lymphoma - Pipeline Review, H1 2016
出版日期: 2016年05月25日 內容資訊: 英文 542 Pages
簡介

所謂濾泡型淋巴瘤是一般的非何杰金氏淋巴瘤(NHL)。也是發展緩慢的淋巴癌,是從白血球的B細胞產生。同時又被稱為「緩慢性」、「低惡性」淋巴癌。主要發病於高齡者,常見的症狀有淋巴結肥大。其他症狀有發燒、體重減輕、發汗、倦怠感等。不同的患者有不同的療法,進行外科手術、放射線治療、化療等。

本報告提供濾泡型淋巴瘤的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

濾泡型淋巴瘤概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

調查中的治療藥:各大學/研究機關

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

開發中的產品:各企業

調查中的產品:各大學/研究機關

開發治療藥的企業

  • AbbVie Inc.
  • Affimed GmbH
  • Bayer AG
  • BeiGene, Ltd.
  • Bio-Path Holdings, Inc.
  • Biocon Limited
  • Biogenomics Limited
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Celldex Therapeutics, Inc.
  • Celltrion, Inc.
  • Cellular Biomedicine Group, Inc.
  • Coherus BioSciences, Inc.
  • CTI BioPharma Corp.
  • Curis, Inc.
  • Dynavax Technologies Corporation
  • Eisai
  • EpiZyme, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Genentech, Inc.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline Plc
  • Hutchison MediPharma Limited
  • Immune Design Corp.
  • ImmunoGen, Inc.
  • Immunomedics, Inc.
  • Infinity Pharmaceuticals, Inc.
  • Johnson & Johnson
  • Juno Therapeutics Inc.
  • Karyopharm Therapeutics, Inc.
  • Kite Pharma, Inc.
  • Les Laboratoires Servier SAS
  • MedImmune, LLC
  • Medivation, Inc.
  • MEI Pharma, Inc.
  • Merck & Co., Inc.
  • Millennium Pharmaceuticals, Inc.
  • Mirati Therapeutics Inc.
  • MorphoSys AG
  • Nordic Nanovector ASA
  • Novartis AG
  • 小野藥品工業
  • Pfizer Inc.
  • Pharmacyclics, Inc.
  • Portola Pharmaceuticals, Inc.
  • ProNAi Therapeutics, Inc.
  • Sandoz International GmbH
  • Seattle Genetics, Inc.
  • 武田藥品工業
  • TG Therapeutics, Inc.

治療藥的評估

  • 單獨療法的情況
  • 聯合治療的情況
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

開發中產品的最新趨勢

暫停的計劃

開發中止的產品

產品開發的里程碑

  • 最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC7999IDB

Summary

Global Markets Direct's, 'Follicular Lymphoma - Pipeline Review, H1 2016', provides an overview of the Follicular Lymphoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Follicular Lymphoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Follicular Lymphoma and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Follicular Lymphoma
  • The report reviews pipeline therapeutics for Follicular Lymphoma by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Follicular Lymphoma therapeutics and enlists all their major and minor projects
  • The report assesses Follicular Lymphoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Follicular Lymphoma

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Follicular Lymphoma
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Follicular Lymphoma pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
  • Introduction
  • Follicular Lymphoma Overview
  • Therapeutics Development
  • Follicular Lymphoma - Therapeutics under Development by Companies
  • Follicular Lymphoma - Therapeutics under Investigation by Universities/Institutes
  • Follicular Lymphoma - Pipeline Products Glance
  • Follicular Lymphoma - Products under Development by Companies
  • Follicular Lymphoma - Products under Investigation by Universities/Institutes
  • Follicular Lymphoma - Companies Involved in Therapeutics Development
  • Follicular Lymphoma - Therapeutics Assessment
  • Drug Profiles
  • Follicular Lymphoma - Recent Pipeline Updates
  • Follicular Lymphoma - Dormant Projects
  • Follicular Lymphoma - Discontinued Products
  • Follicular Lymphoma - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Follicular Lymphoma, H1 2016
  • Number of Products under Development for Follicular Lymphoma - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Development by Companies, H1 2016 (Contd..1)
  • Number of Products under Development by Companies, H1 2016 (Contd..2)
  • Number of Products under Development by Companies, H1 2016 (Contd..3)
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Products under Development by Companies, H1 2016 (Contd..2)
  • Products under Development by Companies, H1 2016 (Contd..3)
  • Products under Development by Companies, H1 2016 (Contd..4)
  • Products under Development by Companies, H1 2016 (Contd..5)
  • Products under Investigation by Universities/Institutes, H1 2016
  • Follicular Lymphoma - Pipeline by AbbVie Inc., H1 2016
  • Follicular Lymphoma - Pipeline by Affimed GmbH , H1 2016
  • Follicular Lymphoma - Pipeline by Bayer AG, H1 2016
  • Follicular Lymphoma - Pipeline by BeiGene, Ltd., H1 2016
  • Follicular Lymphoma - Pipeline by Bio-Path Holdings, Inc., H1 2016
  • Follicular Lymphoma - Pipeline by Biocon Limited, H1 2016
  • Follicular Lymphoma - Pipeline by Biogenomics Limited, H1 2016
  • Follicular Lymphoma - Pipeline by Boehringer Ingelheim GmbH, H1 2016
  • Follicular Lymphoma - Pipeline by Bristol-Myers Squibb Company, H1 2016
  • Follicular Lymphoma - Pipeline by Celgene Corporation, H1 2016
  • Follicular Lymphoma - Pipeline by Celldex Therapeutics, Inc., H1 2016
  • Follicular Lymphoma - Pipeline by Celltrion, Inc., H1 2016
  • Follicular Lymphoma - Pipeline by Cellular Biomedicine Group, Inc., H1 2016
  • Follicular Lymphoma - Pipeline by Coherus BioSciences, Inc., H1 2016
  • Follicular Lymphoma - Pipeline by CTI BioPharma Corp., H1 2016
  • Follicular Lymphoma - Pipeline by Curis, Inc., H1 2016
  • Follicular Lymphoma - Pipeline by Dynavax Technologies Corporation, H1 2016
  • Follicular Lymphoma - Pipeline by Eisai Co., Ltd., H1 2016
  • Follicular Lymphoma - Pipeline by EpiZyme, Inc., H1 2016
  • Follicular Lymphoma - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016
  • Follicular Lymphoma - Pipeline by Genentech, Inc., H1 2016
  • Follicular Lymphoma - Pipeline by Gilead Sciences, Inc., H1 2016
  • Follicular Lymphoma - Pipeline by GlaxoSmithKline Plc, H1 2016
  • Follicular Lymphoma - Pipeline by Hutchison MediPharma Limited, H1 2016
  • Follicular Lymphoma - Pipeline by Immune Design Corp., H1 2016
  • Follicular Lymphoma - Pipeline by ImmunoGen, Inc., H1 2016
  • Follicular Lymphoma - Pipeline by Immunomedics, Inc., H1 2016
  • Follicular Lymphoma - Pipeline by Infinity Pharmaceuticals, Inc., H1 2016
  • Follicular Lymphoma - Pipeline by Johnson & Johnson, H1 2016
  • Follicular Lymphoma - Pipeline by Juno Therapeutics Inc., H1 2016
  • Follicular Lymphoma - Pipeline by Karyopharm Therapeutics, Inc., H1 2016
  • Follicular Lymphoma - Pipeline by Kite Pharma, Inc., H1 2016
  • Follicular Lymphoma - Pipeline by Les Laboratoires Servier SAS, H1 2016
  • Follicular Lymphoma - Pipeline by MedImmune, LLC, H1 2016
  • Follicular Lymphoma - Pipeline by Medivation, Inc., H1 2016
  • Follicular Lymphoma - Pipeline by MEI Pharma, Inc., H1 2016
  • Follicular Lymphoma - Pipeline by Merck & Co., Inc., H1 2016
  • Follicular Lymphoma - Pipeline by Millennium Pharmaceuticals, Inc., H1 2016
  • Follicular Lymphoma - Pipeline by Mirati Therapeutics Inc., H1 2016
  • Follicular Lymphoma - Pipeline by MorphoSys AG, H1 2016
  • Follicular Lymphoma - Pipeline by Nordic Nanovector ASA, H1 2016
  • Follicular Lymphoma - Pipeline by Novartis AG, H1 2016
  • Follicular Lymphoma - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016
  • Follicular Lymphoma - Pipeline by Pfizer Inc., H1 2016
  • Follicular Lymphoma - Pipeline by Pharmacyclics, Inc., H1 2016
  • Follicular Lymphoma - Pipeline by Portola Pharmaceuticals, Inc., H1 2016
  • Follicular Lymphoma - Pipeline by ProNAi Therapeutics, Inc., H1 2016
  • Follicular Lymphoma - Pipeline by Sandoz International GmbH, H1 2016
  • Follicular Lymphoma - Pipeline by Seattle Genetics, Inc., H1 2016
  • Follicular Lymphoma - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016
  • Follicular Lymphoma - Pipeline by TG Therapeutics, Inc., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Follicular Lymphoma Therapeutics - Recent Pipeline Updates, H1 2016
  • Follicular Lymphoma - Dormant Projects, H1 2016
  • Follicular Lymphoma - Dormant Projects (Contd..1), H1 2016
  • Follicular Lymphoma - Dormant Projects (Contd..2), H1 2016
  • Follicular Lymphoma - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Follicular Lymphoma, H1 2016
  • Number of Products under Development for Follicular Lymphoma - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Top 10 Molecule Types, H1 2016
  • Number of Products by Stage and Top 10 Molecule Types, H1 2016
Back to Top